First to benefit from a deal between Glaxosmithkline plc (GSK) and Avalon Ventures that will launch as many as 10 new companies is Sitari Pharmaceuticals Inc., funded with $10 million in Series A money to pursue early work targeting the transglutaminase 2 (TG2) pathway.